Here’s a timeline that should make you pay attention. June 2024: Adcytherix incorporates with €30 million in seed funding. October 2025: they close a €105 million Series A — the largest ADC-focused Series A in Europe that year. March 2026: first patient dosed in a Phase 1 trial. That’s incorporation to clinic in 21 months. In the ADC space, where development timelines routinely stretch five-plus years, that’s… not normal.

But then again, these aren’t normal founders. Adcytherix was built by the same team that created Emergence Therapeutics, a French ADC and topoisomerase I payload specialist that was acquired by — wait for it — Eli Lilly in June 2023. So the founders know the buyer. They know the science. And now they’re doing it again with what they say is a better platform.

ADCX-020 is an antibody-drug conjugate carrying an exatecan payload (topoisomerase 1 inhibitor) with what the company describes as an optimized linker designed to improve therapeutic index over earlier-generation ADCs. The Phase 1 is the standard playbook — dose escalation in advanced solid tumors followed by expansion cohorts in relapsed or refractory populations — but the enrollment target of 290 patients suggests they’re planning for a serious expansion phase.

The investor syndicate tells its own story. The Series A was led by Bpifrance with Kurma Partners, Andera Partners, and Angelini Ventures, joined by Surveyor Capital (a Citadel company), aMoon, and existing backers including Pontifax, DawnBiopharma (KKR-controlled), Pureos Bioventures, and RA Capital. That’s crossover money at the Series A. In ADCs. In Marseille, France. The confidence here isn’t subtle.

Most ADC companies spend years in preclinical optimization. Adcytherix is sprinting, and with €135 million in total funding and a team that’s already built and sold an ADC company, they have the resources and credibility to pull it off. The ADC space is red-hot. These founders know the playbook because they already ran it once.